Genetic study maps out prostate cancer hope

A landmark genetic study described as the ‘Rosetta stone’ of prostate cancer has opened up a new era of hope for men with advanced forms of the disease.

The findings could lead to a plethora of personalised medicines that target specific gene defects, some of which are already in use or undergoing trials.

It sets the stage for a whole new world of treatment options for patients with metastatic cancer spreading to their bones and vital organs who no longer respond to existing therapies.